ARTICLE | Clinical News
Histogenics completes enrollment in Phase III of NeoCart implant
August 17, 2017 11:47 PM UTC
Histogenics Corp. (NASDAQ:HSGX) said it completed enrollment of 245 patients in a Phase III trial of its NeoCart cell therapy implant vs. standard of care (SOC) microfracture surgery to repair knee cartilage injuries.
The open-label, North American trial is evaluating the primary endpoint of change in physical functioning and pain from baseline to 1 year per both Knee injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) score. The secondary endpoint is cartilage repair as measured by MRI...
BCIQ Company Profiles